CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) contiguous announced the assignment of Claire M. Fraser, Ph.D., to its Board of Directors. Dr. Fraser volition statesman serving connected Seres’ Board, effectual immediately.
“It is an incredibly breathtaking clip to beryllium joining the Seres Board of Directors arsenic the institution prepares for its archetypal imaginable merchandise support with SER-109 successful recurrent C. difficile infection,” said Dr. Fraser. “In my view, the occurrence of SER-109 bodes good for Seres’ broader pipeline of caller objective candidates utilizing microbiome therapeutics arsenic a caller attack for Infection Protection for medically compromised individuals and antimicrobial absorption much generally. I look guardant to being a portion of a institution moving diligently to proceed to bring the committedness of specified microbiome therapeutics to patients.”
Dr. Fraser is the Director of The Institute for Genome Sciences, which she launched successful 2007, astatine the University of Maryland School of Medicine. She besides serves arsenic a module subordinate successful the Departments of Medicine and Microbiology/Immunology. Prior to this, she held positions arsenic President and Director of The Institute for Genomic Research; Chief of the Section connected Molecular Neurobiology successful the Laboratory of Physiologic and Pharmacologic Studies astatine the National Institute connected Alcohol Abuse and Alcoholism; Senior Staff Fellow and Chief of the Unit of Receptor Regulation, Receptor Biochemistry and Molecular Biology astatine the Laboratory of Molecular and Cellular Neurobiology wrong the National Institutes of Health; and a Cancer Research Scientist astatine Roswell Park Memorial Institute.
She graduated from Rensselaer Polytechnic Institute successful Troy, NY and received her Ph.D. successful pharmacology from the State University of New York astatine Buffalo. She was elected arsenic a subordinate of the National Academy of Medicine successful 2011 and precocious concluded a word arsenic President of the American Association for the Advancement of Science (AAAS).
“I look guardant to collaborating with Dr. Fraser, whose enactment has provided important contributions that person supported the emergence of the microbiome manufacture for years,” said Eric Shaff, President and Chief Executive Officer of Seres. “We proceed to beforehand our pipeline, delving deeper into our Infection Protection strategy to code unmet needs successful medically compromised individuals, including those with crab neutropenia, cirrhosis, and coagulated organ transplant. Dr. Fraser’s acquisition volition service arsenic the cleanable complement to the cognition and improvement expertise we person built astatine Seres implicit the past decade.”
“Dr. Fraser brings heavy expertise driving guardant the subject of the microbiome and we expect her to beryllium an invaluable summation to our Board supporting the improvement of aboriginal microbiome medicines and the continued occurrence of Seres,” said Stephen Berenson, Chairman of the Board of Seres and Managing Partner of Flagship Pioneering.
In summation to the absorption connected SER-109, Seres continues to marque advancement connected its SER-155 objective study. Seres precocious completed enrollment of Cohort 1 successful its SER-155 objective survey and, aft a palmy pre-planned gathering successful December 2022 with the study’s Data and Safety Monitoring Board (DSMB) to reappraisal SER-155 Cohort 1 information data, plans to statesman enrollment of Cohort 2 successful aboriginal 2023. In addition, the Company plans to denote archetypal information and pharmacological data, including cause bacterial taxon engraftment from Cohort 1, successful aboriginal 2023.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is simply a starring microbiome therapeutics institution processing a caller people of multifunctional bacterial consortia that are designed to functionally interact with big cells and tissues to dainty disease. Seres’ SER-109 programme achieved the first-ever affirmative pivotal objective results for a targeted microbiome cause campaigner and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 programme is being precocious to forestall further recurrences of C. difficile infection and has imaginable to go a first-in-class FDA-approved oral microbiome therapeutic. Seres is evaluating SER-155 successful a Phase 1b survey successful patients receiving allogeneic hematopoietic stem compartment transplantation to trim incidences of gastrointestinal infections, bloodstream infections and graft-versus-host illness arsenic good arsenic further preclinical signifier programs targeting Infection Protection successful medically compromised patients. The Company is besides conducting probe to pass further improvement of microbiome therapeutics for ulcerative colitis.
For much information, delight sojourn www.serestherapeutics.com.
Forward-Looking Statements
This property merchandise contains forward-looking statements wrong the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained successful this property merchandise that bash not subordinate to matters of humanities information should beryllium considered forward-looking statements, including Dr. Fraser’s assignment and the anticipated interaction thereof, the imaginable support and motorboat of SER-109; the imaginable for microbiome therapeutics to support against infection; and different statements which are not humanities fact.
These forward-looking statements are based connected management’s existent expectations. These statements are neither promises nor guarantees, but impact known and chartless risks, uncertainties and different important factors that whitethorn origin our existent results, show oregon achievements to beryllium materially antithetic from immoderate aboriginal results, show oregon achievements expressed oregon implied by the forward-looking statements, including, but not constricted to, the following: we person incurred important losses, are not presently profitable and whitethorn ne'er go profitable; our request for further funding; our constricted operating history; the interaction of the COVID-19 pandemic; our unproven attack to therapeutic intervention; the lengthy, costly and uncertain process of objective cause development; our reliance connected 3rd parties and collaborators to behaviour our objective trials, manufacture our merchandise candidates and make and commercialize our merchandise candidates, if approved; and our quality to clasp cardinal unit and to negociate our growth. These and different important factors discussed nether the caption “Risk Factors” successful our Quarterly Report connected Form 10-Q filed with the Securities and Exchange Commission (SEC), connected November 2, 2022, and our different reports filed with the SEC could origin existent results to disagree materially from those indicated by the forward-looking statements made successful this property release. Any specified forward-looking statements correspond management’s estimates arsenic of the day of this property release. While we whitethorn elite to update specified forward-looking statements astatine immoderate constituent successful the future, we disclaim immoderate work to bash so, adjacent if consequent events origin our views to change. These forward-looking statements should not beryllium relied upon arsenic representing our views arsenic of immoderate day consequent to the day of this property release.
English (US)